719900
Resomer® RG 504 H, Poly(D,L-lactide-co-glycolide)
acid terminated, lactide:glycolide 50:50, Mw 38,000-54,000
Synonym(s):
PLGA
Sign In to View Organizational & Contract Pricing.
Select a Size
Change View
About This Item
Linear Formula:
[C3H4O2]x[C2H2O2]y
CAS Number:
MDL number:
UNSPSC Code:
12162002
NACRES:
NA.23
Quality Level
form
amorphous
feed ratio
lactide:glycolide 50:50
mol wt
Mw 38,000-54,000
degradation timeframe
<3 months
viscosity
0.45-0.60 dL/g, 0.1 % (w/v) in chloroform(25 °C, Ubbelohde) (size 0c glass capillary viscometer)
transition temp
Tg 46-50 °C
storage temp.
2-8°C
SMILES string
O2C(C(=O)OC(C2=O)C)C.O1CC(=O)OCC1=O
InChI
1S/C6H8O4.C4H4O4/c1-3-5(7)10-4(2)6(8)9-3;5-3-1-7-4(6)2-8-3/h3-4H,1-2H3;1-2H2
InChI key
LCSKNASZPVZHEG-UHFFFAOYSA-N
Application
Resomer® RG 504 H, Poly(D, L-Lactide-co-Glycolide) can be used to fabricate a biodegradable hemostyptic device for safe and locally controlled release of thrombin which promotes local blood clot formation.
It can be used to preparepolymer nanospheres for encapsulating CuO, to form stimuli-responsivemultifunctional nanocarriers.
It can be used to preparepolymer nanospheres for encapsulating CuO, to form stimuli-responsivemultifunctional nanocarriers.
Legal Information
Product of Evonik
RESOMER is a registered trademark of Evonik Rohm GmbH
Storage Class
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Niranjan G Kotla et al.
Nanomaterials (Basel, Switzerland), 9(9) (2019-09-05)
There is a pressing clinical need for advanced colon-specific local drug delivery systems that can provide major advantages in treating diseases associated with the colon, such as inflammatory bowel disease (IBD) and colon cancer. A precise colon targeted drug delivery
Hossein Kamali et al.
Materials science & engineering. C, Materials for biological applications, 96, 561-575 (2019-01-05)
An in situ forming gel (ISFG) of buprenorphine (BP) was prepared using PLGA-PEG-PLGA (triblock) and N‑methyl‑2‑pyrrolidone as solvent for decreasing the initial burst release. Supercritical CO2 method was used for ring opening polymerization of triblock. The optimum formulation of ISFG
Maria Kirzhner et al.
Ophthalmology, 120(6), 1300-1304 (2013-02-13)
To compare wrapped and polymer-coated hydroxyapatite implants in children undergoing primary enucleation with no adjuvant therapies. Retrospective, interventional cohort study. All children undergoing primary enucleation without adjuvant therapies between 1999 and 2009 at a tertiary pediatric cancer hospital. Review and